<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857467</url>
  </required_header>
  <id_info>
    <org_study_id>NRL001-01/2008 (SUM)</org_study_id>
    <nct_id>NCT00857467</nct_id>
  </id_info>
  <brief_title>Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.</brief_title>
  <official_title>Randomised, Double-blind, Single Dose, Three-way, Cross-over Study to Investigate the Safety and Response to 1g or 2g Rectal Suppositories Containing 5 mg or 10 mg 1R,2S-methoxamine Hydrochloride [NRL001] or Matching Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a healthy volunteer three-way crossover study. A total of 12 subjects will receive&#xD;
      three single administrations of 1 g rectal suppositories (containing either 5 mg NRL001, 10&#xD;
      mg NRL001 or matching placebo), with a washout period of at least 7 days between dosings. A&#xD;
      further 12 subjects will receive three single administrations of 2 g rectal suppositories&#xD;
      (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), again with a 7 day washout&#xD;
      period between dosings. The pharmacodynamic response, pharmacokinetics and safety profile&#xD;
      will be determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MARP after a single dose</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic plasma assessment to determine systemic uptake</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular parameters; heart rate and blood pressure</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>1 g suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 g suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL001</intervention_name>
    <description>Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.</description>
    <arm_group_label>1 g suppository</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL001</intervention_name>
    <description>Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.</description>
    <arm_group_label>2 g suppository</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. No previous history of ano-rectal conditions or diseases&#xD;
&#xD;
          2. No history of cardiovascular disease&#xD;
&#xD;
          3. 18 to 60 years of age&#xD;
&#xD;
          4. Males and females (pre-menopausal females of child-bearing potential must be using&#xD;
             adequate contraceptive methods and have a negative pregnancy test before the start of&#xD;
             the study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of medication in the last 30 days with a vasodilatory activity, or use of any&#xD;
             medication currently or within the last 30 days which the Investigator believes may&#xD;
             affect the study participation or results&#xD;
&#xD;
          2. Use of monoamine oxidase inhibitors presently or within the last 2 weeks before study&#xD;
             participation&#xD;
&#xD;
          3. Use of any medication in the last 30 days applied to the anus and/or via the rectum&#xD;
&#xD;
          4. Application of any unlicensed medication within the previous 3 months or participation&#xD;
             in any other research study in the last three months which involved being paid a&#xD;
             disturbance allowance; having an invasive procedure (e.g. venepuncture &gt;50ml,&#xD;
             endoscopy) or exposure to ionising radiation.&#xD;
&#xD;
          5. Regular intake of more than 21 units of alcohol per week&#xD;
&#xD;
          6. History or any evidence of cardiovascular disease including ischaemic heart disease&#xD;
             and hypertension (defined on examination: systolic blood pressure greater than 160&#xD;
             mmHg or diastolic blood pressure greater than 90 mmHg; based on at least two separate&#xD;
             readings), peripheral vascular disease or Raynaud's syndrome&#xD;
&#xD;
          7. Presence of diabetes mellitus&#xD;
&#xD;
          8. History or symptoms of thyroid diseases, including hypo- or hyperthyroidism&#xD;
&#xD;
          9. Pregnant or lactating females&#xD;
&#xD;
         10. History of any clinically relevant allergy&#xD;
&#xD;
         11. Presence of concomitant gastrointestinal diseases or disorders, such as significant&#xD;
             abdominal symptoms and haemorrhoids but also any significant organ (e.g. renal,&#xD;
             hepatic or cardiac) dysfunction&#xD;
&#xD;
         12. Volunteers whom the Investigator feels would not comply with the requirements of the&#xD;
             trial&#xD;
&#xD;
         13. Volunteers who have been exposed to more than 5 mSv of ionising radiation in the last&#xD;
             12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-JÃ¼rgen Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John H Scholefield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of GI Surgery, Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>December 21, 2009</last_update_submitted>
  <last_update_submitted_qc>December 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

